Fennec up on U.S. approval of hearing loss therapy

Fennec Pharmaceuticals

21/09/2022 13:16

** Shares of Fennec Pharmaceuticals Inc  FENC.O  rise ~2% to
$7.78 before the bell
    ** U.S. FDA approved FENC intravenous therapy to prevent
chemotherapy-induced hearing loss in children  urn:newsml:reuters.com:*:nL4N30S21J
    ** Pedmark is now only approved therapy to prevent
cisplatin-induced hearing loss in U.S.
    ** Cisplatin is used in treating a range of cancers in
children such as liver, bone and brain cancer, but can cause
permanent hearing loss
    ** Up to Tuesday's close, stock up ~73% YTD

 (Reporting by Khushi Mandowara)
 ((Khushi.Mandowara@thomsonreuters.com;))